Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the primary results from the Phase IIIb STRONG trial (NCT03084471), which primarily investigated the safety of fixed-dose durvalumab monotherapy in patients with urinary tract carcinoma. Durvalumab was granted accelerated FDA approval in 2017 for use in this setting but due to the Phase III DANUBE trial failing to meet its primary endpoints in 2020, durvalumab has since been withdrawn from the market. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.